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Pulmonary hypertension is characterized by increased pulmonary artery pressure and car-
ries an increased mortality. Population-based studies into pulmonary hypertension are
scarce and little is known about its prevalence in the general population. We aimed to
describe the distribution of echocardiographically-assessed pulmonary artery systolic pres-
sure (ePASP) in the general population, to estimate the prevalence of pulmonary hyperten-
sion, and to identify associated factors.
Methods
Participants (n = 3381, mean age 76.4 years, 59% women) from the Rotterdam Study, a
population-based cohort, underwent echocardiography. Echocardiographic pulmonary hy-
pertension was defined as ePASP>40 mmHg.
Results
Mean ePASP was 26.3 mmHg (SD 7.0). Prevalence of echocardiographic pulmonary hy-
pertension was 2.6% (95%CI: 2.0; 3.2). Prevalence was higher in older participants com-
pared to younger ones (8.3% in those over 85 years versus 0.8% in those between 65 and
70), and in those with underlying disorders versus those without (5.9% in subjects with
COPD versus 2.3%; 9.2% in those with left ventricular systolic dysfunction versus 2.3%;
23.1% in stages 3 or 4 left ventricular diastolic dysfunction versus 1.9% in normal or stage
1). Factors independently associated with higher ePASP were older age, higher BMI, left
ventricular diastolic dysfunction, COPD and systemic hypertension.
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Conclusion
In this large population-based study, we show that pulmonary hypertension as mea-
sured by echocardiography has a low prevalence in the overall general population in
the Netherlands, but estimates may be higher in specific subgroups, especially in those
with underlying diseases. Increased pulmonary arterial pressure is likely to gain impor-
tance in the near future due to population aging and the accompanying prevalences of
underlying disorders.
Introduction
Pulmonary hypertension (PH) is a severe disorder defined by a mean pulmonary artery pres-
sure of 25 mmHg at rest [1–4]. Pulmonary hypertension can occur as an isolated disease or
as a consequence of a number of underlying diseases and conditions, such as heart failure and
chronic obstructive pulmonary disease (COPD) [4–11]. Although higher levels of pulmonary
pressure have been associated with increased mortality both in patients and in the general pop-
ulations, general population prevalence estimates are scarce [7, 10, 12–15].
The diagnostic method of choice for PH is right-heart catheterization [1]. However, its inva-
sive nature renders it unsuitable in population-based studies. Transthoracic Doppler echocar-
diography is a non-invasive tool used in clinical practice for screening and monitoring of PH
progression. Although some studies describe under- or overestimation of pulmonary arterial
pressures by echocardiography, a meta-analysis has shown it to have good sensitivity (83%),
reasonable specificity (72%) and a correlation 0.7 with invasively acquired measurements [16,
17]. Most deviations from measurements by right heart catheterization seem to occur in pa-
tients with very high pressure estimates [18]. In echocardiograms, the pulmonary artery systol-
ic pressure is the most frequently used parameter.
We aimed to describe the distribution of echocardiographic pulmonary artery systolic pres-
sure (ePASP) and to estimate the prevalence of pulmonary hypertension measured by echocar-
diography (ePH) in the general population. Furthermore, we sought to identify factors
independently associated with ePASP.
Material and Methods
Setting
This study was embedded in the Rotterdam Study, an ongoing population-based, prospective
cohort study, which started in 1990–1993 in a suburb of Rotterdam, the Netherlands. The
design and rationale has been described in detail elsewhere [19]. Briefly, the original subco-
hort (RS-I) enrolled 7983 participants aged 55 years or older. Two additional subcohorts
(RS-II, n = 3011 participants of 55 years and older; and RS-III, n = 3768 participants of
45 years and older) were recruited into the study in 2000–2001 and 2006–2008, respectively.
Every 3–4 years the participants are invited for re-examination. Information routinely col-
lected includes anthropometry, cardiovascular risk factors, medication use, and extensive
functional and imaging tests [19]. Left- and right-sided echocardiographic measurements are
available only for the most recent follow-up round of RS-I (fifth follow-up) and RS-II (third
follow-up) (from 2009 to 2012). Participants from those two subcohorts who visited the re-
search centre were eligible for this study.
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Echocardiography
Three trained echocardiographers obtained resting transthoracic echocardiograms in all partic-
ipants visiting the research center. The standardized protocol included 2-dimensional scanning
in the parasternal long and short axis views, apical and subcostal views. In addition, left ventric-
ular dimensions were measured using 2-dimension guided M-mode. Tricuspid regurgitation
peak velocity (TRV) was measured using Continuous Wave Doppler. Tissue Doppler imaging
was done in the apical 4-chamber view.
Echocardiograms were made using a commercially available ultrasonography system (Vivid
I, GE Healthcare, Little Chalfont, UK), with a 2.5 MHz transducer. All images obtained were
digitally stored and assessed offline by the echocardiographers. Abnormal findings were con-
firmed by clinical experts and communicated to the participants and their general practitioners
according to a pre-defined protocol.
Pulmonary Artery Systolic Pressure
Pulmonary artery systolic pressure was calculated as the sum of the estimated right atrial
pressure (RAP) and the pressure gradient over the tricuspid valve [20] as: ePASP = 4TRV2 +
RAP. The pressure gradient was computed from the highest Doppler tricuspid regurgitation
velocity gathered from several windows using the simplified Bernoulli equation (4TRV2) [20].
RAP was estimated according to the guidelines of the American Society of Echocardiography:
if the inferior vena cava diameter was 21 mm and its forced inspiratory collapse (“sniff
test”) was> 50%, RAP was estimated to be 3 mmHg; if the diameter was> 21 mm and the
collapse< 50%, RAP was estimated as 15 mmHg; in intermediate cases, a value of 8 mmHg
was assigned[20].
Participants were deemed to have ePH if they had ePASP> 40 mmHg[2, 20, 21]. If data on
RAP was missing, a tricuspid pressure gradient> 36 mmHg (TRV> 3.0 m/s) criterion was
used instead. Participants in whom TRV was too small to measure or absent were included in
the prevalence analyses as non-cases, as we they were most likely to have normal pulmonary
pressures.
Left ventricular function
As ejection fraction was not available in our cohort, we assessed left ventricular (LV) function
through LV fractional shortening. LV fractional shortening (%) at the endocardium was calcu-
lated by: (LV end-diastolic diameter—LV end-systolic diameter) / LV end-diastolic diameter 
100% [22]. LV systolic dysfunction was defined as a LV fractional shortening< 29% [23].
Pulsed Doppler recordings of transmitral filling velocities were obtained in the apical
4-chamber view, with the sample volume placed in the mitral valve orifice near the tips of the
leaflets. Doppler peak E and peak A velocities were averaged over three cycles. Early mitral
valve velocity deceleration time was measured as the time between the peak E wave and the
upper deceleration slope extrapolated to the zero baseline. The E/E’ ratio was calculated by di-
viding E-top velocity by early diastolic longitudinal velocity of the septal mitral annulus E’-top.
LV diastolic function was categorized in line with previous publications [24, 25], using an algo-
rithm which takes into account E/A ratio, E/E’ ratio and E’, dividing participants into 3
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categories of diastolic function: normal or relaxation abnormality (stage 1), pseudonormal
(stage 2), and restrictive (including both reversible [stage 3] and fixed [stage 4] LV diastolic
dysfunction). For participants with atrial fibrillation, the categorization was based on mitral
valve inflow deceleration time instead of the E/A ratio [24, 25].
Other covariates
Anthropometric and laboratory measurements were assessed in a standardized manner during
the same visit as the echocardiography. Body mass index (BMI) was calculated as weight (kg) /
height squared (m2). Systemic hypertension was defined as blood pressure 140/90 mmHg or
use of anti-hypertensive medication (Anatomical Therapeutic Chemical [ATC] codes C02,
C03, C07, C08 and C09). Blood pressure was averaged between two measurements, taken with
the participant in sitting position. Diabetes mellitus was defined as either fasting glucose
level> 7.0 mmol/L, or a non-fasting glucose level> 11.0 mmol/L (if fasting serum was un-
available) or use of anti-diabetic medication (ATC code A10) [26, 27]. Smokers were classified
into never, former and current smokers. COPD was diagnosed by an obstructive spirometry
(proportion of the forced vital capacity exhaled in the first second [FEV1/FVC]< 70%) at the
research centre or by a pulmonologist or general practitioner. Participants with a spirometry
suggestive of a restrictive syndrome and asthma patients were not considered to have COPD.
Sensitivity analysis
We also estimated ePH prevalence using 2 alternative definitions. The first one included those
with a dilated right-ventricle (basal right ventricular end-diastolic diameter > 42 mm) in addi-
tion to those with ePASP> 40 mmHg[20]. This was done to take into account variables sug-
gestive of PH beyond ePASP, as recommended by the European Society of Cardiology [1]. The
second definition used a more stringent ePASP threshold of 50 mmHg or a tricuspid pressure
gradient of 46 mmHg (TRV> 3.4 m/s) instead of the 40 mmHg cut-off [1], without taking
right ventricular diameter into account.
Statistical analyses
Prevalence estimates with confidence intervals (Wald) of ePH were calculated for the full popu-
lation and for subgroups defined by age, sex, smoking status, BMI, and presence of LV systolic
dysfunction, LV diastolic dysfunction, COPD, systemic hypertension and diabetes mellitus.
To identify factors associated with ePASP, we created 2 linear regression models. In model
A, each factor was adjusted for age and sex. Model B was a multivariate model in which all vari-
ables that were significant in model A were entered simultaneously.
Missing data (maximum proportion of missing values per covariate: 6%) was imputed with
a multiple imputation procedure (5 imputations) using the Markov Chain Monte Carlo meth-
od. TRV, RAP and right ventricular end-diastolic diameter were used as predictors in the im-
putation model, but were not imputed. Missing data on smoking and COPD was dealt with
using the last observation carried forward method.
We used Stata version 12 (StataCorp. College Station, TX, U.S.) and IBM SPSS Statistics ver-
sion 20.0 (IBM Corp. Armonk, NY, U.S.) for the statistical analysis.
Results
The response-rate for the analysed rounds of examination was 63.4% for RS-I and 75.1% for
RS-II, yielding a total of 3381 participants eligible for the study. Of those, we excluded 558
(16.5%) due to the fact that no data on the tricuspid regurgitation jet were recorded. The
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excluded population was younger, with a higher proportion of men, diabetics and current or
past smokers, had better ventricular diastolic and lower systolic function and a higher BMI
(Table 1). The final study population was composed of 2823 participants with a mean age of
76.4 years (SD 6.2), 59% women, 10.4% had COPD and 3.5% had LV diastolic dysfunction
stages 3 or 4 (Table 1).
Prevalence of ePH
The overall prevalence of ePH in our study was 2.6% (95%CI 2.0; 3.2). Older participants, and
those with COPD, LV systolic or diastolic dysfunction had a significantly higher prevalence of
ePH than their counterparts (Table 2).
An enlarged right ventricle was strongly associated with higher ePASP, even after adjust-
ments for age, sex and BMI (p< 0.001). Sensitivity analyses accounting for it (that is, using a
definition of ePH based on either an ePASP of> 40 mmHg or a right ventricular end-diastolic
dimension> 42 mm) yielded an overall prevalence of 4.5% (95%CI 3.7; 5.2) with a significantly
higher prevalence in men than women (6.2% vs 3.2%, p< 0.001; Table 3). A more stringent
ePASP threshold of 50 mmHg, regardless of RV size, yielded an overall prevalence of 0.5%
(95%CI: 0.2; 0.8), and no sex difference (p = 0.91).
Factors independently associated with ePASP
In 208 participants, data on right atrial pressure were missing and in 670 participants, we could
not measure tricuspid regurgitation velocity because the regurgitation jet was either absent or
Table 1. Participant characteristics.
Study population (n = 2823) Excluded population (n = 558)
n Mean (SD) or % n Mean (SD) or % p
Age, years 2823 76.4 (6.2) 558 74.7 (5.8) <0.001
Women 2823 59% 558 53% 0.01
Body mass index, kg/m2 2811 27.2 (4.0) 548 29.3 (4.7) <0.001
Smoking 2823 558 0.004
Never 997 35.3% 158 28.3%
Former 1566 55.5% 336 60.2%
Current 260 9.2% 64 11.5%
TRV, m/s 2153 2.3 (0.3) NA NA
RAP, mmHg 2473 3.9 (2.2) 368 3.7 (1.8) 0.02
ePASP, mmHg 1945 26.3 (7.0) NA NA
RVEDD, mm 2558 33.0 (4.4) 380 32.7 (4.1) 0.16
FS, % 2788 41.1 (5.9) 497 40.4 (6.3) 0.01
LV systolic dysfunction 2788 4.2% 497 4.0% 0.89
LV diastolic dysfunction 2790 510 0.002
Normal and stage 1 1716 61.5% 353 69.2%
Stage 2 977 35.0% 147 28.8%
Stages 3 and 4 97 3.5% 10 2.0%
COPD 2823 10.4% 558 9.7% 0.60
Diabetes mellitus 2706 12.8% 519 21.8% <0.001
Systemic hypertension 2773 87.1% 545 89.7% 0.08
TRV = tricuspid regurgitation peak velocity; RAP = right atrial pressure; ePASP = pulmonary artery systolic pressure; RVEDD = right ventricular end-
diastolic diameter; FS = left ventricular fractional shortening; LV = left ventricle; COPD = chronic obstructive pulmonary disease.
doi:10.1371/journal.pone.0130072.t001
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too small to measure. Hence, ePASP could only be estimated in 1945 of the 2823 participants.
In those, mean ePASP was 26.3 mmHg (SD 7.0) and the median was 25.3 mmHg (inter-quar-
tile range 21.5; 29.8). It followed a slightly right-skewed distribution (Fig 1).
In the fully adjusted model, a 10-year increase in age was associated with a 2.2 mmHg (95%
CI 1.8; 2.7) higher ePASP. A 5 kg/m2 increase in BMI was associated with a 0.7 mmHg (95%CI
0.3; 1.1) pressure increment (Table 4). In comparison with participants with normal LV
Table 2. Prevalence of echocardiographic pulmonary hypertension, overall and in subgroups.
ePH prevalence (95% CI) p
Overall 2.6% (2.0; 3.2)
Sex Women 2.6% (1.8; 3.4) 0.93
Men 2.7% (1.7; 3.6)
Age 65 to 70 years 0.8% (0.02; 1.6) <0.001
70 to 75 years 1.6% (0.7; 2.5)
75 to 80 years 1.8% (0.9; 2.8)
80 to 85 years 4.1% (2.4; 5.9)
85 years or older 8.3% (5.0; 11.6)
Smoking Never 2.7% (1.7; 3.7) 0.32
Former 2.8% (2.0; 3.6)
Current 1.2% (0.0; 2.5)
Body mass index < 25 kg/m2 2.4% (1.4; 3.4) 0.66
 25 kg/m2 2.7% (2.0; 3.4)
COPD Yes 5.9% (3.1; 8.5) 0.001
No 2.3% (1.7; 2.8)
Systemic hypertension Yes 2.8% (2.1; 3.5) 0.15
No 1.4% (0.2; 2.7)
Diabetes mellitus Yes 4.1% (2.0; 6.2) 0.07
No 2.4% (1.8; 3.0)
LV systolic dysfunction Yes 9.2% (4.0; 14.4) < 0.001
No 2.3% (1.8; 2.9)
LV diastolic dysfunction Normal or stage 1 1.9% (1.2; 2.5) < 0.001
Stage 2 2.8% (1.7; 3.8)
Stages 3 and 4 23.1% (11.3; 34.9)
COPD = chronic obstructive pulmonary disease; LV = left ventricle; ePH = pulmonary hypertension.
doi:10.1371/journal.pone.0130072.t002
Table 3. Prevalence of echocardiographic-defined pulmonary hypertension, alternative diagnostic criteria.
Diagnostic criteria
ePASP > 40 mmHg ePASP > 40 mmHg or right ventricle > 42 mm ePASP > 50 mmHg
(n = 2823) p (n = 2828) p (n = 2823) p
Overall 2.6% (2.0; 3.2) 4.5% (3.7; 5.2) 0.5% (0.2; 0.8)
Women 2.6% (1.8; 3.4) 0.93 3.2% (2.4; 4.0) <0.001 0.5% (0.1; 0.9) 0.91
Men 2.7% (1.7; 3.6) 6.2% (4.7; 7.6) 0.5% (0.2; 0.8)
Data are shown as prevalences (95% conﬁdence interval)
RAP = right atrial pressure; TRV = tricuspid regurgitation velocity; ePASP = pulmonary artery systolic pressure, calculated as 4*TRV2 + RAP. If RAP
could not be estimated, the case deﬁnition was based on TRV > 3.0 m/s and 3.4 m/s to correspond to ePASP > 40 mmHg and 50 mmHg, respectively
Participants with absent or too-small-to-measure TRV were included as non-cases.
doi:10.1371/journal.pone.0130072.t003
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diastolic function or stage 1 LV diastolic dysfunction, participants with LV diastolic dysfunc-
tion stages 3 or 4 had higher ePASP estimates (7.1 mmHg change, 95%CI 5.0; 9.1). Sex, LV
fractional shortening and diabetes mellitus were significantly associated with ePASP in model
A, adjusting for age and sex, but were not after further adjustments. Systemic hypertension was
significantly associated with higher ePASP even after adjusting for other factors (1.3 mmHg
change; 95%CI 0.4; 2.1).
Discussion
Overall, we found that pulmonary hypertension as assessed by echocardiography has a preva-
lence of 2.6% in the general population in the Netherlands. The prevalence of ePH was higher
in older persons, and in those with COPD, LV systolic or diastolic dysfunction. Factors inde-
pendently associated with higher ePASP in a multivariate model were older age, higher BMI,
left ventricular diastolic dysfunction, COPD and systemic hypertension.
Prevalence of ePH
Increased levels of pulmonary pressure has been associated with increased all-cause mortality
in the general population, as well as increased admission rates in heart failure patients [15, 28].
Yet, data on the prevalence of increased ePASP in the general population is scarce [29]. Given
Fig 1. Distribution of pulmonary artery systolic pressure in 1945 participants in whom it could be estimated.
doi:10.1371/journal.pone.0130072.g001
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the population aging and the known association of PH with heart and lung diseases, an increas-
ing PH prevalence could be expected [29]. The prevalence of ePASP> 40 mmHg has recently
been estimated to be 8% in healthy volunteers aged> 50 years in Italy and ePH was found in
6.8% of participants in an African-American population [30, 31]. A study in Armadale re-
ported a prevalence of 9.1%[21]. However, this estimate may be inflated, as the study included
participants referred for echocardiography, likely representing a population with increased risk
as compared to the general population. Still, our estimates are low, considering that the popula-
tions in the other studies were likely to be as healthy or healthier than ours based on age and
comorbidities [30, 31]. Our case-definition method (that is, including those with absent or un-
measurable TRV as non-cases, instead of excluding them) may have led to conservative esti-
mates. Removal of those participants from the analyses, hence basing the definition of ePH on
ePASP or TRV (in those without RAP) measurements only, yields a 3.4% prevalence estimate.
Additional exclusion of participants without an RAP estimate, thus basing the cases only on
ePASP, yields a prevalence of 3.6%, still leaving part of the difference unexplained.
The prevalence of pulmonary hypertension in patients with COPD has been reported to be
as high as 47–49% in clinical studies [6, 7]. Such difference from our estimates (5.9%) may be
explained by differences in study populations (patient cohorts versus general population) [6,
7]. Our population likely does not include the most severe cases of COPD, as they may have
been unable to visit the research centre.
Since the European Society of Cardiology suggests the inclusion of “additional echocardio-
graphic variables suggestive of PH” in the echocardiographic assessment of PH, secondary
analyses were done with an additional criterion (dilated right ventricle) [1]. This increased
prevalence estimates to 4.5% with a significant difference between men and women (6.2%
Table 4. Associations with pulmonary artery systolic pressure in linear regression models in 1945 participants in whom ePASP could be
estimated.
Model A Model B
Change in ePASP, mmHg Change in ePASP, mmHg
(95%CI) p (95%CI) p
Age, per 10 years 2.6 (2.1; 3.1) <0.001 2.2 (1.8; 2.7) <0.001
Women -0.7 (-1.3; -0.1) 0.03 -0.6 (-1.2; 0.004) 0.05
Body mass index, per 5 kg/m2 0.8 (0.4; 1.1) <0.001 0.7 (0.3; 1.1) 0.001
Smoking 0.67
Never Reference
Former -0.3 (-1.0; 0.4)
Current -0.2 (-1.4; 0.9)
LV fractional shortening, per 10% -1.0 (-1.5; -0.5) <0.001 -0.5 (-1.0; 0.06) 0.09
LV diastolic dysfunction <0.001 <0.001
Normal and stage 1 Reference Reference
Stage 2 1.1 (0.5; 1.7) 1.1 (0.4; 1.7)
Stages 3 and 4 7.8 (5.7; 9.8) 7.1 (5.0; 9.1)
COPD 2.3 (1.3; 3.3) <0.001 2.4 (1.4; 3.4) <0.001
Diabetes mellitus 1.0 (0.003; 2.0) 0.05 0.3 (-0.7; 1.3) 0.56
Systemic hypertension 1.8 (0.9; 2.7) <0.001 1.3 (0.4; 2.1) 0.01
Dependent variable is ePASP (mmHg).
LV = left ventricular; COPD = chronic obstructive pulmonary disease; 95%CI = 95% conﬁdence interval.
In model A, each variable is adjusted for age and sex.
In model B, adjustments were made for all the variables which had p < 0.05 in model A.
doi:10.1371/journal.pone.0130072.t004
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versus 3.2%, p< 0.001). The overall larger size of the right ventricle in men probably underlies
this difference. We also performed analyses with a more stringent threshold of 50 mmHg,
which yielded a prevalence of 0.5% and no sex-related differences.
ePASP and associated factors
Our ePASP estimates (median 25.3 mmHg and mean 26.3 mmHg) were similar to values re-
ported in three previously published studies, even though the other population were younger
and overall healthier [15, 30, 32]. As ePASP is known to increase with older age, we had ex-
pected a greater difference [6, 15, 30, 33]. Patterns of age-related ePASP increase may be vari-
able across generations and locations, therefore longitudinal studies would serve well in
elucidating the trajectories of pulmonary pressures across the life course [15, 30, 33].
We did not find sex-related differences in the prevalence of ePH, and sex was not indepen-
dently associated with ePASP. Previous literature is divided on this point, as some studies have
found differences and others have not [6, 7, 15, 31, 33].
LV fractional shortening was not found to be independently associated with ePASP, despite
our finding of a significantly higher ePH prevalence in those with LV systolic dysfunction
(9.2% versus 2.3%, p< 0.001). Others also could not demonstrate consistent associations be-
tween ejection fraction and ePASP[10, 15]. Instead, literature suggests that ePASP is more as-
sociated with LV diastolic function, as we also demonstrated[10].
Strengths of this study are the large sample size and the population-based nature. Other
strong points are a structured and standardized echocardiographic assessment and the avail-
ability of large number of covariates. One of the limitations is the lack of the diagnostic gold
standard for PH, right heart catheterization[1, 2]. Right heart catheterization is unsuitable for a
general-population setting because of its invasive nature. Echocardiography is frequently used
as the first step in PH evaluation[2]. Although echocardiographic estimates of pulmonary arte-
rial pressure may over or underestimate invasive measurements, they deviate most at the very
high end of the pulmonary arterial pressure spectrum, particularly in poor quality exams [34].
In this study, the vast majority of the population have normal pulmonary pressures and only
2% of the exams were deemed of poor quality. Furthermore, echocardiography has a sensitivity
of 83%, a specificity of 72%, and a correlation of 0.7 with invasively acquired estimates [16, 17].
Thus, although echocardiography should not be used for clinical diagnosis of PH, it is arguably
one of the best exams available for epidemiologic research. We only had ePASP estimates for
57% of the cohort, but we were able to include 83% of it in the ePH prevalence analyses. In
comparison, a similar study reported that 69% of their participants had analyzable jets [15].
Lastly, our population is elderly and predominantly white, so caution should be taken to gener-
alize it to other age groups and ethnicities.
Conclusions
Pulmonary hypertension as measured by echocardiography has low prevalence in the overall
general population in the Netherlands, but estimates may be higher in specific subgroups, espe-
cially in those with left ventricular dysfunction or COPD. BMI and systemic hypertension were
associated with ePASP independently of heart or lung disease.
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